Trisol Medical

Executive Summary

Trisol Medical is an Israeli med‑tech company pioneering a next‑generation transcatheter tricuspid valve replacement (TTVR) system for patients with severe tricuspid regurgitation who are unsuitable for surgery. Its flagship Trisol Valve features a nitinol frame with a dome‑shaped leaflet designed to eliminate regurgitation while preserving right‑ventricular function, addressing a critical unmet need in structural heart disease. The fully percutaneous, low‑profile device offers a potential alternative to surgical repair, which historically has high morbidity in this frail population. Currently in preclinical development, the company is leveraging foundational research to refine device design and prepare for first‑in‑human studies. With the tricuspid valve market growing rapidly due to an aging population and limited treatment options, Trisol Medical is well‑positioned to capture a share, provided successful clinical validation. The company's innovation, combined with a strong intellectual property portfolio, underpins its potential to become a leader in the interventional cardiology space.

Upcoming Catalysts (preview)

• Q2 2027Initiation of First‑in‑Human Feasibility Study40% success
• Q1 2027Series A Financing Round Completion60% success
• Q4 2026FDA or CE Mark Submission for Investigational Device Exemption (IDE)50% success